Positions
- Professor
-
Department of Pathology & Immunology
ÌÇÐÄÊÓƵ of Medicine
Houston, Texas, United States
Addresses
- Texas Children's Hospital (Lab)
-
Department of Pathology
1102 Bates Street FC830.20
Houston, TX, 77030
United States
Education
- MSc from University of Buenos Aires, School of Clinical Pathology and Pharmacy
- Buenos Aires, Buenos Aires, Argentina
- PhD from University of Buenos Aires, School of Clinical Pathology and Pharmacy
- Buenos Aires, Buenos Aires, Argentina
- Clinical Pathology
- Postdoctoral Fellowship at National Institutes of Health
- Bethesda, Maryland, United States
- Postdoctoral Fellowship at Memorial Sloan-Kettering Cancer Center
- New York, New York, United States
Professional Interests
- Genetic regulation of blood formation including the immune system
- Pathobiology and treatment of myeloid and lymphoid leukemia
- Mechanisms of self-renewal in normal and leukemic hematopoietic stem cells
Selected Publications
-
Yamada T, Park CS, Mamonkin M, Lacorazza HD. " " Nat. Immunol.. 2009 Jun ; 10 (6) : 618-26.
Pubmed PMID: . -
Shen Y, Park CS, Suppipat K, Mistretta TA, Puppi M, Horton TM, Rabin K, Gray NS, Meijerink JP, Lacorazza HD.. " " Leukemia. 2017 ;
Pubmed PMID: . -
Park, C.S.; Lewis, AH, Chen, TJ, Bridges, CS, Shen, Y, Suppipat, K, Puppi, M, Tomolonis, JA, Pang, PD, Mistretta, TA, Ma, L, Green, MR, Rau, R, Lacorazza, HD. " " Blood. 2019 Nov 28; 134 (22) : 1960-1972.
Pubmed PMID: . -
Bridges CS, Chen TJ, Puppi M, Rabin KR, Lacorazza HD. " Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia. " Blood Advances. 2023 Feb 14; 7 (3) : 422-435.
Funding
-
Targeting DYRK2 stability to eradicate leukemia stem cells in chronic myeloid leukemia
#R01 CA283079-01A1 - Grant funding from National Cancer Institute
-
A molecular approach to dissecting MEK-mediated phosphorylation in pediatric leukemia
#R01 CA285402-01A1 - Grant funding from National Cancer Institute
-
Discovery of MAP2K7 Inhibitors Through DNA-Encoded Chemical Screens to Treat T-Cell Acute Lymphoblastic Leukemia
#1R21CA286412-01A1 - Grant funding from National Cancer Institute
to edit your profile